“…Discovered in 1940 and its structure determined in 1963, CBD acts on multiple pathways in the brain and modulates the psychoactive effects of Δ 9 ‐tetrahydrocannabinol (THC) (Zuardi et al ., 1982; Malone et al ., 2009; Mannucci et al ., 2017; Murphy et al ., 2017; Crippa et al ., 2018; Mokrysz et al ., 2020). CBD alone has recently been investigated for its therapeutic potential in psychiatric phenotypes including anxiety, depression, sociality, drug craving, and others in animal studies and a limited number of clinical trials (Table SI) (Zuardi et al ., 1993; Ren et al ., 2009; El‐Alfy et al ., 2010; Bergamaschi et al ., 2011; Crippa et al ., 2011; Réus et al ., 2011; Schubart et al ., 2011; Campos et al ., 2012; Leweke et al ., 2012; de Mello Schier et al ., 2014; de Carvalho and Takahashi, 2017; Osborne et al ., 2017a; Bhattacharyya et al ., 2018; Mandolini et al ., 2018; McGuire et al ., 2018; Masataka 2019; de Faria et al ., 2020; Sales et al ., 2020; Skelley et al ., 2020). Previously studied mechanisms of CBD action include indirect stimulation of endocannabinoid receptor CB1 via delayed hydrolysis and reuptake of the endocannabinoid anandamide ( AEA ), action at the serotonin 1a ( 5HT‐1a ), peroxisome proliferator‐activated receptor gamma ( PPARγ ), and transient receptor potential cation channel subfamily V ( TRPV ) receptors, neuroprotection, stimulation of neurogenesis, and antioxidant activity (Alline C. Campos et al ., 2013; Alline Cristina Campos and Guimarães, 2008; Hampson et al ., 1998; Pumroy et al ., 2019; Schiavon et al ., 2016; Vallée et al ., 2017).…”